

Kilitch Drugs eyes African markets to fuel growth

• Setup of manufacturing unit on 12400 sqm of land in Ethiopia

Kilitch Drugs (India) Ltd. (KDIL), has informed that, it has planned to focus on African markets with a state-of-the-art Cephalosporin injectable plant near Adis Ababa - capital city of Ethiopia. The unit will have a capacity of 20 million vials and commence operations in FY 2019 - 2020. Besides vials, the plant will also produce tablets, capsules, dry syrup, etc.

'By 2020, KDIL plans to register more than 500 products in the African markets, which is the next bastion for growth. Africa is a highly complex but profitable market. Our presence there would mean a potential doubling of revenues and significant improvement in margins' — Mr. Mukund Mehta, Managing Director, elaborated.

KDIL is the first company in Ethiopia to have a dedicated Cephalosporin injectable plant along with other Oral dosage forms. Oromia Region Investment commission has allocated additional 5700 sq. meter of land, hence total land allocated is 12,400 sq. meter for aforesaid expansion, added Mr. Mehta.

For Kilitch Drugs (India) Limited

Harshal Patil Company Secretary







